Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin
[Display omitted] The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations...
Gespeichert in:
| Veröffentlicht in: | International journal of pharmaceutics 2016-12, Vol.514 (2), p.399-406 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 2 |
| container_start_page | 399 |
| container_title | International journal of pharmaceutics |
| container_volume | 514 |
| creator | Marshall, Lindsay J. Oguejiofor, Wilson Price, Robert Shur, Jagdeep |
| description | [Display omitted]
The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations directly to the biofilms. Unfortunately, current aerosolised antibiotic regimes are unable to efficiently eradicate these biofilms from the airways. We investigated the ability of the innate antimicrobial, lactoferrin, to enhance the activity of two aminoglycoside antibiotics (tobramycin and gentamicin) against biofilms of P. aeruginosa strain PAO1. Biofilms were prepared in 96 well polystyrene plates. Combinations of the antibiotics and various lactoferrin preparations were spray dried. The bacterial cell viability of the various spray dried combinations was determined. Iron-free lactoferrin (apo lactoferrin) induced a 3-log reduction in the killing of planktonic cell by the aminoglycoside antibiotics (p |
| doi_str_mv | 10.1016/j.ijpharm.2016.09.034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837287319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S037851731630864X</els_id><sourcerecordid>1837287319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-b5d9c36c43ec77d1921828ec3ea9e4cfef457af86236d5435818dd372874f5e53</originalsourceid><addsrcrecordid>eNqFkLFu2zAQhomgRey4fYQUGrtIIUVJpKYgMJI0QIAs7UzQ5DE-QxJdUnbhty9luV0zHQ78fh7-j5BbRgtGWXO3K3C33-rQF2VaC9oWlFdXZMmk4DmvRPOJLCkXMq-Z4AtyE-OOUtqUjF-TRSmaUgrJlyS8DEeII77rEf2QeZeNW8hg2OrBgM30MGKPJvgN6i7TZsQjjqcJM77f4DCnbDhle__HQsgwJbs0nQ_9oTs_xwnvUtY7CAGHL-Sz012Er5e5Ir-eHn-uf-Svb88v64fX3FSyHPNNbVvDG1NxMEJY1pZMlhIMB91CZRy4qhbayabkja0rXksmreUiFatcDTVfke_zv_vgfx9SSdVjNNB1egB_iIrJM8xZm9B6RlPTGAM4tQ_Y63BSjKpJt9qpi2416Va0VUl3yn27nDhserD_U__8JuB-BiAVPSIEFQ3CpBYDmFFZjx-c-AsL-pae</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1837287319</pqid></control><display><type>article</type><title>Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Marshall, Lindsay J. ; Oguejiofor, Wilson ; Price, Robert ; Shur, Jagdeep</creator><creatorcontrib>Marshall, Lindsay J. ; Oguejiofor, Wilson ; Price, Robert ; Shur, Jagdeep</creatorcontrib><description>[Display omitted]
The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations directly to the biofilms. Unfortunately, current aerosolised antibiotic regimes are unable to efficiently eradicate these biofilms from the airways. We investigated the ability of the innate antimicrobial, lactoferrin, to enhance the activity of two aminoglycoside antibiotics (tobramycin and gentamicin) against biofilms of P. aeruginosa strain PAO1. Biofilms were prepared in 96 well polystyrene plates. Combinations of the antibiotics and various lactoferrin preparations were spray dried. The bacterial cell viability of the various spray dried combinations was determined. Iron-free lactoferrin (apo lactoferrin) induced a 3-log reduction in the killing of planktonic cell by the aminoglycoside antibiotics (p<0.01) and also reduced both the formation and persistence of P. aeruginosa biofilms (p<0.01). Combinations of lactoferrin and an aminoglycoside displays potential as an effective new therapeutic strategy in the treatment of P. aeruginosa biofilms infections such as those typical of the CF lungs.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2016.09.034</identifier><identifier>PMID: 27628783</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Anti-Infective Agents - administration & dosage ; Anti-Infective Agents - chemistry ; Anti-Infective Agents - pharmacology ; Antimicrobial protein ; Apoproteins - administration & dosage ; Apoproteins - chemistry ; Apoproteins - pharmacology ; Biofilms ; Biofilms - drug effects ; Cell Survival - drug effects ; Cystic fibrosis ; Drug Compounding ; Drug Synergism ; Dry powder inhalers ; Gentamicins - pharmacology ; Lactoferrin - administration & dosage ; Lactoferrin - chemistry ; Lactoferrin - pharmacology ; Powders ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Spray drying ; Tobramycin - pharmacology</subject><ispartof>International journal of pharmaceutics, 2016-12, Vol.514 (2), p.399-406</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-b5d9c36c43ec77d1921828ec3ea9e4cfef457af86236d5435818dd372874f5e53</citedby><cites>FETCH-LOGICAL-c482t-b5d9c36c43ec77d1921828ec3ea9e4cfef457af86236d5435818dd372874f5e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2016.09.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27628783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marshall, Lindsay J.</creatorcontrib><creatorcontrib>Oguejiofor, Wilson</creatorcontrib><creatorcontrib>Price, Robert</creatorcontrib><creatorcontrib>Shur, Jagdeep</creatorcontrib><title>Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations directly to the biofilms. Unfortunately, current aerosolised antibiotic regimes are unable to efficiently eradicate these biofilms from the airways. We investigated the ability of the innate antimicrobial, lactoferrin, to enhance the activity of two aminoglycoside antibiotics (tobramycin and gentamicin) against biofilms of P. aeruginosa strain PAO1. Biofilms were prepared in 96 well polystyrene plates. Combinations of the antibiotics and various lactoferrin preparations were spray dried. The bacterial cell viability of the various spray dried combinations was determined. Iron-free lactoferrin (apo lactoferrin) induced a 3-log reduction in the killing of planktonic cell by the aminoglycoside antibiotics (p<0.01) and also reduced both the formation and persistence of P. aeruginosa biofilms (p<0.01). Combinations of lactoferrin and an aminoglycoside displays potential as an effective new therapeutic strategy in the treatment of P. aeruginosa biofilms infections such as those typical of the CF lungs.</description><subject>Anti-Infective Agents - administration & dosage</subject><subject>Anti-Infective Agents - chemistry</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Antimicrobial protein</subject><subject>Apoproteins - administration & dosage</subject><subject>Apoproteins - chemistry</subject><subject>Apoproteins - pharmacology</subject><subject>Biofilms</subject><subject>Biofilms - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cystic fibrosis</subject><subject>Drug Compounding</subject><subject>Drug Synergism</subject><subject>Dry powder inhalers</subject><subject>Gentamicins - pharmacology</subject><subject>Lactoferrin - administration & dosage</subject><subject>Lactoferrin - chemistry</subject><subject>Lactoferrin - pharmacology</subject><subject>Powders</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Spray drying</subject><subject>Tobramycin - pharmacology</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLFu2zAQhomgRey4fYQUGrtIIUVJpKYgMJI0QIAs7UzQ5DE-QxJdUnbhty9luV0zHQ78fh7-j5BbRgtGWXO3K3C33-rQF2VaC9oWlFdXZMmk4DmvRPOJLCkXMq-Z4AtyE-OOUtqUjF-TRSmaUgrJlyS8DEeII77rEf2QeZeNW8hg2OrBgM30MGKPJvgN6i7TZsQjjqcJM77f4DCnbDhle__HQsgwJbs0nQ_9oTs_xwnvUtY7CAGHL-Sz012Er5e5Ir-eHn-uf-Svb88v64fX3FSyHPNNbVvDG1NxMEJY1pZMlhIMB91CZRy4qhbayabkja0rXksmreUiFatcDTVfke_zv_vgfx9SSdVjNNB1egB_iIrJM8xZm9B6RlPTGAM4tQ_Y63BSjKpJt9qpi2416Va0VUl3yn27nDhserD_U__8JuB-BiAVPSIEFQ3CpBYDmFFZjx-c-AsL-pae</recordid><startdate>20161205</startdate><enddate>20161205</enddate><creator>Marshall, Lindsay J.</creator><creator>Oguejiofor, Wilson</creator><creator>Price, Robert</creator><creator>Shur, Jagdeep</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161205</creationdate><title>Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin</title><author>Marshall, Lindsay J. ; Oguejiofor, Wilson ; Price, Robert ; Shur, Jagdeep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-b5d9c36c43ec77d1921828ec3ea9e4cfef457af86236d5435818dd372874f5e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anti-Infective Agents - administration & dosage</topic><topic>Anti-Infective Agents - chemistry</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Antimicrobial protein</topic><topic>Apoproteins - administration & dosage</topic><topic>Apoproteins - chemistry</topic><topic>Apoproteins - pharmacology</topic><topic>Biofilms</topic><topic>Biofilms - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cystic fibrosis</topic><topic>Drug Compounding</topic><topic>Drug Synergism</topic><topic>Dry powder inhalers</topic><topic>Gentamicins - pharmacology</topic><topic>Lactoferrin - administration & dosage</topic><topic>Lactoferrin - chemistry</topic><topic>Lactoferrin - pharmacology</topic><topic>Powders</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Spray drying</topic><topic>Tobramycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marshall, Lindsay J.</creatorcontrib><creatorcontrib>Oguejiofor, Wilson</creatorcontrib><creatorcontrib>Price, Robert</creatorcontrib><creatorcontrib>Shur, Jagdeep</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marshall, Lindsay J.</au><au>Oguejiofor, Wilson</au><au>Price, Robert</au><au>Shur, Jagdeep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2016-12-05</date><risdate>2016</risdate><volume>514</volume><issue>2</issue><spage>399</spage><epage>406</epage><pages>399-406</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations directly to the biofilms. Unfortunately, current aerosolised antibiotic regimes are unable to efficiently eradicate these biofilms from the airways. We investigated the ability of the innate antimicrobial, lactoferrin, to enhance the activity of two aminoglycoside antibiotics (tobramycin and gentamicin) against biofilms of P. aeruginosa strain PAO1. Biofilms were prepared in 96 well polystyrene plates. Combinations of the antibiotics and various lactoferrin preparations were spray dried. The bacterial cell viability of the various spray dried combinations was determined. Iron-free lactoferrin (apo lactoferrin) induced a 3-log reduction in the killing of planktonic cell by the aminoglycoside antibiotics (p<0.01) and also reduced both the formation and persistence of P. aeruginosa biofilms (p<0.01). Combinations of lactoferrin and an aminoglycoside displays potential as an effective new therapeutic strategy in the treatment of P. aeruginosa biofilms infections such as those typical of the CF lungs.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27628783</pmid><doi>10.1016/j.ijpharm.2016.09.034</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2016-12, Vol.514 (2), p.399-406 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1837287319 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-Infective Agents - administration & dosage Anti-Infective Agents - chemistry Anti-Infective Agents - pharmacology Antimicrobial protein Apoproteins - administration & dosage Apoproteins - chemistry Apoproteins - pharmacology Biofilms Biofilms - drug effects Cell Survival - drug effects Cystic fibrosis Drug Compounding Drug Synergism Dry powder inhalers Gentamicins - pharmacology Lactoferrin - administration & dosage Lactoferrin - chemistry Lactoferrin - pharmacology Powders Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Spray drying Tobramycin - pharmacology |
| title | Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A32%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20the%20enhanced%20antimicrobial%20activity%20of%20combination%20dry%20powder%20inhaler%20formulations%20of%20lactoferrin&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Marshall,%20Lindsay%20J.&rft.date=2016-12-05&rft.volume=514&rft.issue=2&rft.spage=399&rft.epage=406&rft.pages=399-406&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2016.09.034&rft_dat=%3Cproquest_cross%3E1837287319%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1837287319&rft_id=info:pmid/27628783&rft_els_id=S037851731630864X&rfr_iscdi=true |